Project Research

a ddress

**** ******* ***** ***

Land O Lakes, F L 34639

tel 813-***-****

email j ablz44@r.postjobfree.com

JONATHAN

R IOS-DOR IA

P rofile

Accomplished cell and molecular biologist with extensive experience in cancer biology research. Author and Inventor on

several patents in a small biotech company. I am highly organized, skilled at oral communication, work well in

m ultidisciplinary teams.

Education

University of Michigan, Ann Arbor, M I B.S., 1999

Cellular and Molecular Biology

University of Michigan, Ann Arbor, M I Ph.D., 2004

Cellular and Molecular Biology

Patent Applications

1. “Modification of Biological Targeting Groups for the Treatment of Cancer.” 2007. Breitenkamp K, R ios-Doria J,

B reitenkamp R, Sill K, Skaff H. US Patent Application #200********, PCT WO2008134761.

2. “Polymer Micelles Containing SN-38 for the Treatment of Cancer.” 2009. Sill K., Skaff H, Carie A, R ios-Doria J,

Cardoen G, Slama R. USSN 61/175,401.

3. “Polymer Micelles Containing Anthracyclines for the Treatment of Cancer.” 2009. Sill K, Skaff H, R ios-Doria J,

Cardoen G. USSN 61/174,160.

E xpe r ience

Senior Scientist, I ntezyne Technologies Tampa, FL June 2006-Present

• Key contributor in writing patents for novel biotechnology inventions, highly skilled at literature and patent

searching and filing IDS forms.

• Established Intezyne’s tissue culture research laboratory from the ground up in a new facility, directed laboratory

design and acquired equipment and instrumentation.

• Lead preclinical development of Intezyne’s targeted, chemotherapy-drug loaded nanoparticles.

• Supervise and t rain junior staff members.

• Develop novel analytical methods/in vitro assays to characterize nanoparticles and t ranslate them into animal

studies.

• Guided experimental design that generated valuable preclinical data which directly attracted >$1 million in

f inancial investments in the company.

• Led siRNA delivery project that resulted in the development of effective siRNA-loaded nanoparticles to be

delivered to cancer cells.

• Led research project identifying cancer stem cells in an engineered cell line resistant to topoisomerase I

i nhibitors.

• C reated over 20 SOPs for the biological laboratory that resulted in increased productivity for biological staff

members.

• I dentified ways to cut R&D costs by 10% but maintain efficiency in the laboratory.

Postdoctoral Fellow, Moffitt Cancer Center Tampa, FL Sept. 2004-May 2006

• Generated stable Histone GFP-expressing HeLa cells with over 90% GFP positive.

• Developed a novel three-color f low cytometric assay for detection of mitosis and apoptosis in GFP-transfected

cells.

• Employed shRNA against proteins in DNA damage pathway to sensitize cancer cells to radiation-induced

apoptosis.

Graduate Student Assistant, University of M ichigan Comprehensive Cancer Center, A nn Arbor, M I Sept.

1999-August 2004

• F irst to identify E-cadherin and Beta-catenin as substrates of calpain protease.

• Correlated E-cadherin and Beta-catenin proteolytic cleavage in primary tumor tissue vs. normal.

Skills

Proficient in mammalian and bacterial cell culture, stable cell line generation, clonogenic assays, DNA and siRNA

t ransfection/in vivo delivery, DNA cloning, f low cytometry, FACS, immunofluorescence, confocal microscopy, SDS-

PAGE, agarose electrophoresis, Western, Northern and Southern blotting, immunoprecipitation, apoptosis, proteolysis

and t ranscriptional reporter assays, cytotoxicity assays, cell-based fluorescent and luminescent assays, Real-Time

PCR, ELISA, HPLC.

Publications

1. Rashid MG, Sanda MG, Vallorosi CJ, R ios-Doria J, Rubin MA, and Day ML. Post-t ranslational t runcation and

i nactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. 2001. Cancer Res.

61: 481-492.

2. Rios-Doria J, Day KC, Rashid MG, Kuefer R, Chinnaiyan AM, Rubin MA, and Day ML. The role of calpain in the

p roteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. 2003. J. Biol. Chem. 278: 1372-1379.

3. Rios-Doria J, Kuefer R, Ethier SP, and Day ML. Cleavage of β-catenin by calpain in prostate ad mammary tumor

P age 2

cells. 2004. Cancer Res. 64: 7237-7240.

4. Rios-Doria J and Day ML. Truncated E-cadherin potentiates cell death in prostate epithelial cells. 2005. The

P rostate. 63: 259-268.

5. Rios-Doria J, Fay A, Velkova A, and Monteiro AN. DNA Damage response: Determining the fate of

phosphorylated histone H2AX. 2006. Cancer Biol. Ther. 5(2): 142-144.

6. Rios-Doria J, Velkova A, Dapic V, Galan-Caridad J, Dapic V, Carvalho M, Melendez J, Monteiro A. Ectopic

expression of histone H2AX mutants reveals a role for its post-t ranslational modifications. 2009. Cancer Biol. Ther.

8(5):422-34.

7. Rios-Doria J, Melendez J, Monteiro A. Three-color intranuclear staining for measuring mitosis and apoptosis in

cells t ransfected with a GFP-tagged histone. 2009. Biotech Histochem. Aug 4:1-5.

8. Rios-Doria J, Carie A, Cardoen G, Burke B, Skaff H, Luetteke N, and Sill K. IT-141, a polymer micelle

encapsulating SN-38, induces tumor regression in multiple colorectal cancer models. Submitted.

I nvited Lectures

1. Rios-Doria J, Chinnaiyan AM, Rubin MA, and Day ML. “Proteolytic regulation of β-Catenin by calpain and

potential role in cancer”. American Association for Cancer Research, Orlando, FL. March 2004.

2. Rios-Doria J, “Polymeric micelles for the t reatment of cancer”. University of South Florida Biotechnology Forum,

September 3rd, 2009.

3. Rios-Doria J, Panelist, Industry/Small Biotech. NIEHS Career Fair, Research Triangle Park, April 30 th, 2010.

Abstracts

1. Rios-Doria J, Day KC, Zhao X, and Day ML. Characterization and functional analysis of an E-Cadherin cytosolic

p roteolytic domain. American Association for Cancer Research, New Orleans, LA. March 2001.

2. Rios-Doria J, Day KC, Zhao X, and Day ML. Characterization and functional analysis of an E-Cadherin cytosolic

p roteolytic domain. Frontiers in Prostate Research Annual Symposium, Wayne State University, M I. April 2001.

3. Rios-Doria J, Day KC, Zhao X, and Day ML. Calpain-mediated inactivation of E-cadherin and processing of β-

catenin in prostate and mammary epithelial cells. American Association for Cancer Research, San Francisco, CA.

April 2002.

4. Rios-Doria, J, Kuefer, R, Chinnaiyan AM, Ethier SP, and Day ML. Cleavage and activation of β-catenin in

p rostate and mammary tumor cells. Michigan Prostate Research Colloquium, Van Andel Institute, Grand Rapids,

M I. May 2004.

5. Rios-Doria J, Velkova A, Galán, J, Dapic V, Melendez J, and Monteiro AN. A role for histone H2AX in cell cycle

control and apoptosis. American Association for Cancer Research, Washington, DC. April 2006.

6. Sill K, R ios-Doria J, Carie A, Cardoen G, Slama R, and Skaff H. SN-38 encapsulated in targeted polymer

m icelles induce tumor regression in multiple colorectal cancer models. American Association for Cancer Research,

Denver, CO April 2009.

7. Rios-Doria J, Carie A, Cardoen G, Sill K. The IVECT method, a versatile micelle for the delivery of

chemotherapeutic drugs. American Association for Cancer Research, Washington DC, April 2010.

8. Carie A, R ios-Doria J, Cardoen G, Costich T, Sill K. Nanoparticle formulation of SN-38 by the IVECT Method

results in a safer, more effective t reatment for colorectal cancer. American Association for Cancer Research,

Washington DC, April 2010.

P rofessional Memberships

Active member, American Association for Cancer Research

Member, Board of Advisors, University of South Florida Masters in Biotechnology Program

J onathan Rios-

Doria

P age 4

Contact this candidate